FDA warns facet impact from Ozempic and extra can result in blindness – NBC New York

Well-liked weight reduction medicine together with Ozempic and Wegovy will carry a brand new warning a couple of potential uncommon facet impact that may typically result in everlasting imaginative and prescient loss, U.S. well being regulators introduced Monday.

The Meals and Drug Administration stated the chance might be added to the labeling of all GLP-1 medicine, the blockbuster drugs used to deal with weight problems, diabetes and several other different medical situations. The category features a dozen injectable or pill-based medicine, together with broadly used manufacturers like Zepbound and Mounjaro.

The attention situation, referred to as non-arteritic anterior ischemic optic neuropathy, may cause vital imaginative and prescient loss. The issue, which has been reported with all GLP-1 medicine, is attributable to decreased blood circulation to the optic nerve, though the underlying trigger is not understood, the FDA stated.

FDA scientists started wanting into the issue after the publication of a 2024 medical paper tying the situation to sure sufferers taking semaglutide, the energetic drug in Eli Lilly’s Ozempic.

An FDA evaluation of greater than 125 scientific trials discovered that the issue occurred in roughly 6 of each 100,000 sufferers who took a GLP-1 for a minimum of one 12 months. The comparable fee for individuals taking a placebo or different sorts of glucose-lowering drugs was lower than 4 per 100,000, the FDA stated.

The company additionally discovered experiences of the issue in its digital reporting system for drug accidents and uncomfortable side effects.

Signs of the issue embody blurred imaginative and prescient, blind spots, distorted colours and different visible disturbances, based on the FDA. Sufferers experiencing such issues ought to contact a well being care skilled instantly, the company stated.